Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.186 EUR | -31.11% | -19.13% | -.--% |
28/05 | Chardan Research Starts iBio With Buy Rating, $5 Price Target | MT |
13/05 | IBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 20.52M 18.93M 1.71B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
Latest transcript on iBio, Inc.
1 week | -19.13% | ||
1 month | -30.08% | ||
3 months | -35.86% | ||
6 months | -73.62% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Brenner
CEO | Chief Executive Officer | 54 | 18/21/18 |
Felipe Duran
DFI | Director of Finance/CFO | 45 | 01/21/01 |
Phan Dillon
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chip Clark
CHM | Chairman | 56 | 23/21/23 |
Linda Armstrong
BRD | Director/Board Member | 61 | 14/20/14 |
Gary Sender
BRD | Director/Board Member | 62 | 14/20/14 |
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- IBIO Stock
- 0JV0 Stock